Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Core Insights - Summit Therapeutics Inc. plans to submit a Biologics License Application (BLA) for ivonescimab in Q4 2025 based on the results of the HARMONi clinical trial [1] Financial Results - The financial results for the third quarter ended September 30, 2025, were reported, although specific figures were not detailed in the provided content [1] Operational Progress - The company is making operational progress with the planned BLA submission for ivonescimab, which is intended to be used in combination with chemotherapy [1]